Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism

Oncologist

Volumn 5, Issue 3, 2000, Pages 215-223

  Spitzer, Thomas R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Allogeneic transplant; Graff versus host disease; Mixed chimerism; Nonmyeloablative therapy

Indexed keywords

BUSULFAN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT;

ALLOGRAFT; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHIMERA; CLINICAL PROTOCOL; DRUG MEGADOSE; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0033935497     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-3-215     Document Type: Article

References (34)

1. Frei EI, Canellos G. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-594.
2. Santos GW, Sensenbrenner LL, Burke PJ et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 1972;4:559-564.
3. Thomas E, Buckner C, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511-533.
4. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-205.
5. Beatty PG, Hansen J, Anasetti C et al. Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant Proc 1989;21:2993-2994.
6. Demirer T, Bucker CD, Lilleby K et al. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. Cancer 1994;74:715-721.
7. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-674.
8. Hagglund L, Bostom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995;16:747-755.
9. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
10. Khouri IF, Keating M, Körbling M et al. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
11. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
12. Sykes M, Preffer F, Saidman SL et al. Mixed lymphohematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 1998;353:1755-1759.
13. Spitzer TR, McAfee S, Sackstein R et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies 2000. Biol Blood Bone Marrow (in press).
14. Sharabi Y, Abraham VS, Sykes M et al. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992;9:191-197.
15. Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys. Transplantation 1995;59:256-262.
16. Storb R, Yi C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacologic immunosuppression after bone marrow transplantation. Blood 1997;89:3048-3054.
17. Sykes M, Szot GL, Swenson K et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor specific tolerance without myelosuppressive conditioning. Nat Med 1997;3:783-788.
18. Pelot MR, Pearson DA, Swenson K et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999;5:133-135.
19. Butturini A, Seeger R, Gale R. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood 1986;68:954-956.
20. Yamaguchi M, Nakoa S, Ueda M et al. Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide. Bone Marrow Transplant 1995;15:787-789.
21. McSweeney P, Niederwieser D, Shizuru J et al. Outpatient allografting with minimal myelosuppressive, immunosuppressive conditioning of low dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF). Blood 1999;94:393a.
22. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989;169:493.
23. Haung C, Fuchimoto Y, Scheier-Dolberg R et al. Stable mixed chimerism and tolerance using a non-myeloablative preparative regimen in a large animal model. JCI 2000;105:173-181.
24. Childs R, Clave E, Contentin N et al. Reduced toxicity and transplant related mortality (TRM) following non-myeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. Blood 1999;94:3234-3241.
25. Kapelushnik J, Or R, Slavin S. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997;20:1109-1110.
26. Woolfrey A, Nash R, Frangoul H et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T-cell immunodeficiency. Blood 1998;92:520a.
27. Dey B, Sykes M, Spitzer TR. Outcomes of recipients of both bone marrow and solid organ transplants. Medicine (Baltimore) 1998;77:355-369.
28. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480-484.
29. Mahmoud H, Fahmy O, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999;24:355-358.
30. Bensinger W, Weaver C, Appelbaum F et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658.
31. Arslan O, Ustun C, Arat M et al. Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia. Hematol Oncol 1998;16:155-162.
32. Solano C, Martinez C, Brunet S et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplant 1998;22:1129-1135.
33. Ustun C, Arlsan O, Beksac M et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 1999;5:28-35.
34. Spitzer T. Collection of bone marrow. In: Collins NH, Gee A, Read EJ, eds. Cellular Therapies: A Clinical Laboratory Approach. Oxford: Isis Medical Media Limited, 1999 (in press).